Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: A metal-analysis

BMC Cancer

Volumn 3, Issue , 2003, Pages

  González Pérez, Antonio ^a,b   García Rodríguez, Luis A ^a   López Ridaura, Ruy ^b  

^a Ctro Espanol Invest Farmacoepidem ^*  (Spain)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT;

BLADDER CANCER; BREAST CANCER; CALCULATION; CANCER LOCALIZATION; CANCER RISK; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; CONFIDENCE INTERVAL; DIGESTIVE SYSTEM CANCER; DRUG USE; ESOPHAGUS CANCER; HUMAN; KIDNEY CANCER; LUNG CANCER; MEDLINE; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; RANDOMIZATION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; STATISTICAL MODEL; STOMACH CANCER; ARTICLE; COLORECTAL TUMOR; FEMALE; MALE; META ANALYSIS; NEOPLASM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ASPIRIN; CASE-CONTROL STUDIES; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; NEOPLASMS;

EID: 3042711948     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-3-28     Document Type: Review

References (76)

1. Thun MJ, Namboodiri MM and Heath CW: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991, 325(23):1593-6.
2. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC and Speizer FE: Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995, 333(10):609-14.
3. Garcéa Rodréguez LA and Huerta-Alvarez C: Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology 2000, 11(4):376-81.
4. Pollard M and Luckert PH: Prolonged antitumor effect of indomethacin on autochthonous intestinal tumors in rats. J Natl Cancer Inst 1983, 70(6):1103-5.
5. Li M, Lotan R, Levin B, Tahara E, Lippman SM and Xu XC: Aspirin induction of apoptosis in esophageal cancer: a potential for chemoprevention. Cancer Epidemiol Biomarkers Prev 2000, 9(6):545-9.
6. Lehnert T, Deschner EE, Karmali RA and DeCosse JJ: Effect of flurbiprofen and 16,16-dimethyl-prostaglandin E2 on gastrointestinal tumorigenesis induced by N-methyl-N′-nitro-Nnitrosoguanidine in rats. I. Squamous epithelium and mesenchymal tissue. J Natl Cancer Inst 1987, 78(5):923-9.
7. Shibata MA, Hirose M, Masuda A, Kato T, Mutai M and Ito N: Modification of BHA forestomach carcinogenesis in rats: inhibition by diethylmaleate or indomethacin and enhancement by a retinoid. Carcinogenesis 1993, 14(7):1265-9.
8. Takahashi M, Furukawa F, Toyoda K, Sato H, Hasegawa R, Imaida K and Hayashi Y: Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis 1990, 11(3):393-5.
9. Lala PK, Al-Mutter N and Orucevic A: Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice. Int J Cancer 1997, 73(3):371-80.
10. Robertson FM, Parrett ML, Joarder FS, Ross M, Abou-Issa HM, Alshafie G and Harris RE: Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas. Cancer Lett 1998, 122(1-2):165-75.
11. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF and Levine AC: Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000, 164:820-5.
12. Jalbert G and Castonguay A: Effects of NSAIDs on NNK-induced pulmonary and gastric tumorigenesis in A/J mice. Cancer Lett 1992, 66(1):21-8.
13. Cohen SM, Zenser TV, Murasaki G, Fukushima S, Mattammal MB, Rapp NS and Davis BB: Aspirin inhibition of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide-induced lesions of the urinary bladder correlated with inhibition of metabolism by bladder prostaglandin endoperoxide synthetase. Cancer Res 1981, 41(9):3355-9.
14. Sjodahl R: Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Extent, mode, and dose dependence of anticancer effects. Am J Med 2001, 110(1A):66S-69S.
15. Thun MJ, Henley SJ and Patrono C: Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002, 94(4):252-66.
16. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R and Fraumeni JF: Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993, 85(4):307-11.
17. Bucher C, Jordan P, Nickeleit V, Torhorst J and Mihatsch MJ: Relative risk of malignant tumors in analgesic abusers: effects of long-term intake of aspirin. Clin Nephrol 1999, 51:67-72.
18. DerSimonian R and Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
19. Begg CB and Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50(4):1088-101.
20. Friedman GD and Ury HK: Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst 1980, 65(4):723-33.
21. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL and Shore RE: Aspirin and epithelial ovarian cancer. Preventive Medicine 2001, 33(6):682-7.
22. Akre K, Ekstrom AM, Signorello LB, Hansson LE and Nyren O: Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. British Journal of Cancer 2001, 84(7):965-8.
23. Anderson KE, Johnson TW, Lazovich D and Folsom AR: Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst 2002, 94(15):1168-71.
24. Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC and Ross RK: Non-steroidal anti-inflammatory drugs and bladder cancer prevention. British Journal of Cancer 2000, 82(7):1364-9.
25. Coogan PF, Rao SR, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD and Shapiro S: The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Preventive Medicine 1999, 29(2):72-6.
26. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD and Shapiro S: Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 2000, 9(1):119-23.
27. Cotterchio M, Kreiger N, Sloan M and Steingart A: Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001, 10(11):1213-7.
28. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR and Greenberg ER: Over-the-counter analgesics and risk of ovarian cancer. Lancet 1998, 351:104-107.
29. Egan KM, Stampfer MJ, Giovannucci E, Rosner BA and Colditz GA: Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 1996, 88(14):988-93.
30. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne ST, Schoenberg JB, West AB, Rotterdam H, Fraumeni JF and Blot WJ: Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998, 7(2):97-102.
31. Funkhouser EM and Sharp GB: Aspirin and reduced risk of esophageal carcinoma. Cancer 1995, 76(7):1116-9.
32. Garidou A, Tzonou A, Lipworth L, Signorello LB, fKalapothaki V and Trichopoulos D: Life-style factors and medical conditions in relation to esophageal cancer by histologic type in a low-risk population. Int J Cancer 1996, 68(3):295-9.
33. Harris RE, Namboodiri K, Stellman SD and Wynder EL: Breast cancer and NSAID use: Heterogeneity of effect in a case-control study. Prev Med 1995, 24:119-20.
34. Harris RE, Namboodiri KK and Farrar WB: Nonsteroidal anti-inflammatory drugs and breast cancer. Epidemiology 1996, 7:203-5.
35. Harris RE, Kasbari S and Farrar WB: Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 1999, 6(1):71-3.
36. Langman MJ, Cheng KK, Gilman EA and Lancashire RJ: Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. Br Med J 2000, 320(7250):1642-6.
37. Moysich KB, Mettlin C, Piver MS, Natarajan N, Menezes RJ and Swede H: Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2001, 10(8):903-6.
38. Nelson JE and Harris RE: Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncology Reports 2000, 7(1):169-70.
39. Norrish AE, Jackson RT and McRae CU: Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998, 77(4):511-5.
40. Paganini-Hill A, Chao A, Ross RK and Henderson BE: Aspirin use and chronic diseases: A cohort study of the elderly. Br Med J 1989, 299:1247-50.
41. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM and Jacobsen SJ: A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002, 77(3):219-25.
42. Rosenberg L, Palmer JR, Rao RS, Coogan PF, Strom BL, Zauber AG, Stolley PD and Shapiro S: A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2000, 9:933-7.
43. Schreinemachers DM and Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994, 5(2):138-46.
44. Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF and Hanley JA: Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. British Journal of Cancer 2000, 83(1):112-20.
45. Tavani A, Gallus S, La Vecchia C, Conti E, Montella M and Franceschi S: Aspirin and ovarian cancer: an Italian case-control study. Annals of Oncology 2000, 11(9):1171-3.
46. Thun MJ, Namboodiri MM, Calle EE, Flanders WD and Heath CW Jr: Aspirin use and risk of fatal cancer. Cancer Research 1993, 53(6):1322-7.
47. Tzonou A, Polychronopoulou A, Hsieh CC, Rebelakos A, Karakatsani A and Trichopoulos D: Hair dyes, analgesics, tranquilizers and perineal talc application as risk factors for ovarian cancer. Int J Cancer 1993, 55:408-10.
48. Zaridze D, Borisova E, Maximovitch D and Chkhikvadze V: Aspirin protects against gastric cancer: results of a case-control study from Moscow, Russia. Int J Cancer 1999, 82(4):473-6.
49. Menezes RJ, Huber KR, Mahoney MC and Moysich KB: Regular use of aspirin and pancreatic cancer risk. BMC Public Health 2002, 2(1):18.
50. Fairfield KM, Hunter DJ, Fuchs CS, Colditz GA and Hankinson SE: Aspirin, other NSAIDs, and ovarian cancer risk (United States). Cancer Causes Control 2002, 13(6):535-42.
51. Harris RE, Beebe-Donk J and Schuller HM: Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep 2002, 9(4):693-5.
52. Leitzmann MF, Stampfer MJ, Ma J, Chan JM, Colditz GA, Willett WC and Giovannucci E: Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002, 11(10):1108-11.
53. Irani J, Ravery V, Pariente JL, Chartier-Kastler E, Lechevallier E, Soulie M, Chautard D, Coloby P, Fontaine E, Bladou F, Desgrandchamps F and Haillot O: Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J Urol 2002, 168(5):1985-8.
54. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Koenig KL and Shore RE: Aspirin and lung cancer in women. Br J Cancer 2002, 87(1):49-53.
55. Moysich KB, Menezes RJ, Ronsani A, Swede H, Reid ME, Cummings KM, Falkner KL, Loewen GM and Bepler G: Regular aspirin use and lung cancer risk. BMC Cancer 2002, 2(1):31.
56. Rosenberg L: Nonsteroidal anti-inflammatory drugs and cancer. Prev Med 1995, 24(2):107-9.
57. Habel LA, Zhao W and Stanford JL: Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 2002, 13(5):427-34.
58. Johnson TW, Anderson KE, Lazovich D and Folsom AR: Association of Aspirin and Nonsteroidal Anti-inflammatory Drug Use with Breast Cancer. Cancer Epidemiol Biomarkers Prev 2002, 11(12):1586-91.
59. Suleiman UL, Harrison M, Britton A, McPherson K and Bates T: H2-receptor antagonists may increase the risk of cardiooesophageal adenocarcinoma: a case-control study. Eur J Cancer Prev 2000, 9(3):185-91.
60. Cheng KK, Sharp L, McKinney PA, Logan RF, Chilvers CE, Cook-Mozaffari P, Ahmed A and Day NE: A case-control study of oesophageal adenocarcinoma in women: a preventable disease. Br J Cancer 2000, 83(1):127-32.
61. Meier CR, Schmitz S and Jick H: Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 2002, 22(3):303-9.
62. Neugut AI, Rosenberg DJ, Ahsan H, Jacobson JS, Wahid N, Hagan M, Rahman MI, Khan ZR, Chen L, Pablos-Mendez A and Shea S: Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol Biomarkers Prev 1998, 7(10):869-73.
63. McLaughlin JK, Blot WJ, Mehl ES and Fraumeni JF: Relation of analgesic use to renal cancer: population-based findings. Natl Cancer Inst Monogr 1985, 69:217-22.
64. McCredie M, Ford JM and Stewart JH: Risk factors for cancer of the renal parenchyma. Int J Cancer 1988, 42(1):13-6.
65. McCredie M, Pommer W, McLaughlin JK, Stewart JH, Lindblad P, Mandel JS, Mellemgaard A, Schlehofer B and Niwa S: International renal-cell cancer study. II. Analgesics. Int J Cancer 1995, 60(3):345-9.
66. Gago-Dominguez M, Yuan JM, Castelao JE, Ross RK and Yu MC: Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer 1999, 81(3):542-8.
67. Horwitz RI and Feinstein AR: The problem of "protopathic bias" in case-control studies. Am J Med 1980, 68(2):255-8.
68. Corley DA, Kerlikowske K, Verma R and Buffler P: Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003, 124(1):47-56.
69. Anderson WF, Umar A, Viner JL and Hawk ET: The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Des 2002, 8(12):1035-62.
70. Baron JA and Sandler RS: Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med 2000, 51:511-23.
71. Shaheen NJ, Straus WL and Sandler RS: Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs. Cancer 2002, 94(4):950-63.
72. McLaughlin JK and Lipworth L: Epidemiologic aspects of renal cell cancer. Semin Oncol 2000, 27(2):115-23.
73. McCredie M, Stewart JH and Day NE: Different roles for phenacetin and paracetamol in cancer of the kidney and renal pelvis. Int J Cancer 1993, 53(2):245-9.
74. Feinstein AR, Walter SD and Horwitz RI: An analysis of Berkson's bias in case-control studies. J Chronic Dis 1986, 39(7):495-504.
75. Barry MJ: NSAIDs and a lower risk of prostate cancer: causation or confounding? Mayo Clin Proc 2002, 77(3):217-8.
76. Poole C and Greenland S: Random-effects meta-analyses are not always conservative. American Journal of Epidemiology 1999, 150:469-475.